BioVie Inc. Announces Pricing of Public Offering of Common Stock

BioVie Inc. Announces Pricing

of Public Offering of Common Stock

SANTA MONICA, Calif., August 8,

2021 (GLOBE NEWSWIRE) - BioVie Inc., (NASDAQ: BIVI) ("BioVie" or the "Company") a clinical-stage

company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders, liver disease and certain

cancers, today announced the pricing of its underwritten public offering of 2,500,000 shares of its Class A common stock at a public offering

price of $8.00 per share, for gross proceeds of $20,000,000, before deducting underwriting discounts, commissions and offering expenses.

In addition, the Company has granted the underwriters a 45 day option to purchase up to an additional 375,000 shares of common stock to

cover over-allotments at the offering price, less the underwriting discount.

ThinkEquity, a division of Fordham

Financial Management, Inc., is acting as the sole book-running manager for the offering. EF Hutton, division of Benchmark Investments,

LLC, is acting as a financial advisor for the offering.

The Company intends to use the net proceeds

from the offering primarily for general corporate purposes.

The securities will be offered and

sold pursuant to a shelf registration statement on Form S-3 (File No. 333-252386), including a base prospectus, filed with the U.S. Securities

and Exchange Commission (the "SEC") on January 22, 2021 and declared effective on February 2, 2021. The offering will be made

only by means of a written prospectus and prospectus supplement that forms a part of the registration statement. A prospectus supplement

and accompanying prospectus describing the terms of the offering will be filed with the SEC on its website at www.sec.gov. Copies of the

prospectus supplement and the accompanying prospectus relating to the offering may be obtained, when available from the offices of ThinkEquity,

a division of Fordham Financial Management, Inc., 17 State Street, 22nd Floor, New York, New York 10004, by telephone at (877) 436-3673

or by email at prospectus@think-equity.com.

This press release shall not constitute

an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction

in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state

BioVie Inc. (NASDAQ: BIVI) is a clinical-stage

company developing transformative therapies to overcome unmet medical needs in chronic debilitating conditions. In liver disease, the

Company's orphan drug candidate BIV201 (continuous infusion terlipressin), with FDA Fast Track status, is being evaluated in a US

Phase 2 study for the treatment of refractory ascites with top-line results expected in early 2022. The Company is also planning a pivotal

Phase 3 study of BIV201 in the treatment of hepatorenal syndrome-acute kidney injury (HRS-AKI) in 2022. BIV201 is administered as a patent-pending

liquid formulation. The active agent is approved in about 40 countries for related complications of advanced liver cirrhosis but is not

available in the US or Japan. In neuro-degenerative disease, BioVie recently acquired the assets of NeurMedix Inc., including NE3107 that

inhibits inflammatory activation of ERK and NFB (e.g. TNF transcription) that leads to neuroinflammation and insulin resistance, but not

their homeostatic functions (e.g. insulin signaling and neuron growth and survival). Both are drivers of Alzheimer's and Parkinson's

diseases. The Company is conducting a potentially pivotal Phase 3 randomized, double blind, placebo controlled, parallel group, multicenter

study to evaluate NE3107 in subjects who have mild to moderate Alzheimer's disease (NCT04669028). An estimated six million Americans suffer

from Alzheimer's. BioVie has initiated this study and is targeting primary completion in late 2022. A Phase 2 study of NE3107 in

Parkinson's disease is planned for later this year, and related compounds have additional potential to treat certain cancers. NE3107

is patented in the United States, Australia, Canada, Europe and South Korea. For more information, visit http://www.biovieinc.com/.

Forward-Looking Statements

This press release contains forward-looking

statements, which may be identified by words such as "expect," "look forward to," "anticipate" "intend,"

"plan," "believe," "seek," "estimate," "will," "project" or words of similar

meaning. Although BioVie Inc. believes such forward-looking statements are based on reasonable assumptions, it can give no assurance that

its expectations will be attained. Actual results may vary materially from those expressed or implied by the statements herein due to

the Company's ability to successfully raise sufficient capital on reasonable terms or at all, available cash on hand and contractual and

statutory limitations that could impair our ability to pay future dividends, our ability to complete our clinical studies and to obtain

approval for our product candidates, to successfully defend potential future litigation, changes in local or national economic conditions

as well as various additional risks, many of which are now unknown and generally out of the Company's control, and which are detailed

from time to time in reports filed by the Company with the SEC, including quarterly reports on Form 10-Q, reports on Form 8-K and annual

reports on Form 10-K. BioVie Inc. does not undertake any duty to update any statements contained herein (including any forward-looking

statements), except as required by law.

For Investor Relations Inquiries: